{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:57:52Z","timestamp":1776211072236,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":51,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ymgme.2020.09.003","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T11:58:08Z","timestamp":1600257488000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations"],"prefix":"10.1016","volume":"131","author":[{"given":"Jeremy N.","family":"Ruskin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Ortemann-Renon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Msihid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leorah","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina","family":"Puga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Judith","family":"Peterschmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald F.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Maison-Blanche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ymgme.2020.09.003_bb0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00431-003-1362-0","article-title":"Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements","volume":"163","author":"Grabowski","year":"2004","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2020.09.003_bb0010","series-title":"OMMBID: The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Gaucher disease","author":"Grabowski","year":"2013"},{"issue":"10","key":"10.1016\/j.ymgme.2020.09.003_bb0015","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","article-title":"Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat","volume":"43","author":"Kamath","year":"2014","journal-title":"Skelet. Radiol."},{"issue":"6","key":"10.1016\/j.ymgme.2020.09.003_bb0020","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2020.09.003_bb0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ajh.25300","article-title":"Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the phase 2 trial","volume":"94","author":"Lukina","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.ymgme.2020.09.003_bb0030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ymgme.2020.09.003_bb0035","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"9985","key":"10.1016\/j.ymgme.2020.09.003_bb0040","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ymgme.2020.09.003_bb0045","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.ymgme.2014.12.058","article-title":"ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results [abstract]","volume":"114","author":"Cox","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2020.09.003_bb0050","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2020.09.003_bb0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcmd.2017.01.006","article-title":"A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: evaluation of frequency, timing, and duration","volume":"68","author":"Peterschmitt","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2020.09.003_bb0060","series-title":"CERDELGA\u2122 (eliglustat) [package insert]","year":"2018"},{"key":"10.1016\/j.ymgme.2020.09.003_bb0065","series-title":"CERDELGA\u2122 84 mg capsules. Summary of Product Characteristics","year":"2018"},{"issue":"5","key":"10.1016\/j.ymgme.2020.09.003_bb0070","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0091270010372387","article-title":"Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers","volume":"51","author":"Peterschmitt","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ymgme.2020.09.003_bb0075","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.ymgme.2014.12.272","article-title":"CYP2D6 phenotype-based dosing of eliglustat [abstract]","volume":"114","author":"Turpault","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.09.003_bb0080","series-title":"Guidance for Industry E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs","year":"2005"},{"issue":"1","key":"10.1016\/j.ymgme.2020.09.003_bb0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/0091270007307881","article-title":"Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review","volume":"48","author":"Garnett","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.ymgme.2020.09.003_bb0095","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1177\/0091270010378408","article-title":"Creation of a knowledge management system for QT analyses","volume":"51","author":"Tornoe","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.ymgme.2020.09.003_bb0100","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0149-2918(04)90170-1","article-title":"Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies","volume":"26","author":"Ball","year":"2004","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.ymgme.2020.09.003_bb0105","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003264","article-title":"Which QT correction formulae to use for QT monitoring?","volume":"5","author":"Vandenberk","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ymgme.2020.09.003_bb0110","series-title":"Physiologically Based Pharmacokinetic Modeling for Assessment of Eliglustat Interaction Potential with CYP2D6 and CYP3A Inhibitors","author":"Chen","year":"2018"},{"issue":"1","key":"10.1016\/j.ymgme.2020.09.003_bb0115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.1013","article-title":"Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective","volume":"104","author":"Shebley","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ymgme.2020.09.003_bb0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ymgme.2019.11.002","article-title":"Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1","volume":"129","author":"Li","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.09.003_bb0125","series-title":"Value of evaluation concentration:QTc relationship in regulatory decision making. Presentation at Evaluation of Concentration: QTc Relationship in Early Clinical Development: Is a thorough QT study necessary?","author":"Garnett","year":"2012"},{"key":"10.1016\/j.ymgme.2020.09.003_bb0130","series-title":"Clinical Pharmacology and Biopharmaceutics Review(S). NDA 205494 Eliglustat Tartrate (Cerdelga) Clinical Pharmacology Review Addendum","author":"Center for Drug Evaluation and Research","year":"2014"},{"issue":"3","key":"10.1016\/j.ymgme.2020.09.003_bb0135","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"1","key":"10.1016\/j.ymgme.2020.09.003_bb0140","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-019-1085-6","article-title":"Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1","volume":"14","author":"Peterschmitt","year":"2019","journal-title":"Orphanet. J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2020.09.003_bb0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tcm.2015.05.006","article-title":"Late sodium current: a mechanism for angina, heart failure, and arrhythmia","volume":"26","author":"Makielski","year":"2016","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.ymgme.2020.09.003_bb0150","first-page":"4(4)","article-title":"Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil","author":"Vicente","year":"2015","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.ymgme.2020.09.003_bb0155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrcardio.2009.245","article-title":"New developments in atrial antiarrhythmic drug therapy","volume":"7","author":"Burashnikov","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"issue":"Suppl. 4","key":"10.1016\/j.ymgme.2020.09.003_bb0160","first-page":"iv37","article-title":"Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias","volume":"9","author":"Shantsila","year":"2007","journal-title":"Europace"},{"issue":"1","key":"10.1016\/j.ymgme.2020.09.003_bb0165","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/CIRCEP.111.963025","article-title":"Reduced ventricular proarrhythmic potential of the novel combined ion-channel blocker AZD1305 versus dofetilide in dogs with remodeled hearts","volume":"5","author":"Johnson","year":"2012","journal-title":"Circ. Arrhythm. Electrophysiol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:28:45Z","timestamp":1761089325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719220301943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":32,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1096719220301943"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.09.003","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}